Archives
Foretinib (GSK1363089): ATP-Competitive Multikinase Inhib...
Foretinib (GSK1363089): ATP-Competitive Multikinase Inhibitor for Robust Tumor Cell Growth Inhibition
Executive Summary: Foretinib (GSK1363089) is a small-molecule ATP-competitive inhibitor targeting multiple receptor tyrosine kinases, including VEGFR and HGF/Met, with IC50 values in the nanomolar range. It suppresses tumor cell proliferation, migration, and invasion in diverse cancer lines, and significantly reduces metastatic tumor burden in xenograft models (Schwartz 2022). Foretinib is highly soluble in DMSO (≥31.65 mg/mL) but insoluble in water and ethanol, requiring careful stock preparation and storage at −20°C (APExBIO). The compound is strictly for research use and not for diagnostic or therapeutic applications. Its robust kinase inhibition profile and validated in vitro/in vivo activity make it a benchmark tool for mechanistic oncology studies.
Biological Rationale
Receptor tyrosine kinases (RTKs) are essential mediators of cancer cell proliferation, survival, and metastasis. Dysregulation of VEGFR and HGF/Met signaling promotes tumor angiogenesis and cell motility. Foretinib (GSK1363089) was developed to inhibit multiple RTKs, including Met, Ron, KDR (VEGFR2), Flt-1, Flt-4 (VEGFR3), KIT, Flt-3, PDGFR α/β, and Tie-2, targeting both primary tumor growth and metastatic spread (Schwartz 2022). Multikinase inhibition allows for suppression of compensatory pathways that often limit monotherapy efficacy in preclinical cancer models. This broad-spectrum approach enables researchers to dissect complex signaling networks and phenotypes related to cancer progression.
Mechanism of Action of Foretinib (GSK1363089)
Foretinib is a small-molecule, orally bioavailable ATP-competitive inhibitor. It binds to the ATP-binding pocket of its target RTKs, preventing phosphorylation and downstream signaling. Foretinib shows sub-nanomolar to low nanomolar IC50 values for its primary targets: Met, Ron, KDR, Flt-1, Flt-4, KIT, Flt-3, PDGFR α/β, and Tie-2 (IC50 range: 0.4–9.6 nmol/L; kinase assays, 25°C, pH 7.4) (APExBIO). In cellular systems, Foretinib inhibits MET phosphorylation with IC50 values around 21–23 nmol/L in PC-3 prostate and B16F10 melanoma cells (Schwartz 2022). Mechanistically, Foretinib blocks hepatocyte growth factor (HGF)-induced cell motility, induces G2/M phase cell cycle arrest, and reduces cell proliferation. These effects have been confirmed in cell motility inhibition assays and live-cell phenotyping platforms (see Mechanistic Insights).
Evidence & Benchmarks
- Foretinib inhibits Met, Ron, KDR, Flt-1, Flt-4, KIT, Flt-3, PDGFR α/β, and Tie-2 kinases with IC50 values of 0.4–9.6 nmol/L in biochemical assays (25°C, buffer pH 7.4) (APExBIO).
- Cellular MET phosphorylation is suppressed in PC-3 and B16F10 cells with IC50 values of 21–23 nmol/L (serum-free medium, 24 h exposure) (Schwartz 2022).
- Foretinib reduces tumor cell migration and invasion in A549 lung, HT29 colon, and B16F10 melanoma cell lines at nanomolar concentrations (Boyden chamber and wound-healing assays, 24–48 h) (Mechanistic Review).
- Oral administration of Foretinib at 30 mg/kg significantly decreases metastatic tumor nodules and tumor weight in ovarian cancer xenograft models (female athymic mice, 28 days, p < 0.01) (Schwartz 2022).
- Solubility: ≥31.65 mg/mL in DMSO; insoluble in water and ethanol (room temperature, neutral pH) (APExBIO).
This article extends prior summaries, such as the Mechanistic Review, by providing updated benchmarks and workflow integration guidance. For a focused discussion on live-cell phenotyping, see Next-Gen Assay Applications, which this article builds upon by summarizing cross-model activity and storage parameters.
Applications, Limits & Misconceptions
Foretinib (GSK1363089) is validated for in vitro and in vivo research on tumor cell growth, migration, and metastasis. Key applications include:
- Cancer cell proliferation and viability assays: Use in MTT/XTT or live-cell imaging platforms to quantify dose-dependent growth inhibition.
- Cell motility inhibition assays: Quantifies suppression of HGF-induced migration/invasion in Boyden chamber and scratch assays (Schwartz 2022).
- In vivo efficacy studies: Reduces tumor burden in ovarian, prostate, and melanoma xenograft models.
- Kinase signaling pathway analysis: Dissects RTK-driven oncogenic signaling in cellular and biochemical systems.
Common Pitfalls or Misconceptions
- Not suitable for diagnostic or clinical use: Foretinib is for research use only; human or veterinary administration is strictly prohibited (APExBIO).
- Insolubility in aqueous buffers: Attempting to dissolve Foretinib in water or ethanol leads to precipitation; always use DMSO for stock solutions.
- Degradation with improper storage: Stock solutions must be stored at −20°C and used promptly to avoid loss of activity.
- Off-target effects at high concentrations: Doses above 10 μM may affect additional kinases, confounding mechanistic specificity.
- Misinterpretation of viability assays: Single-point viability does not distinguish between cytostasis and cytotoxicity; use complementary assays for comprehensive pharmacodynamic readouts (Schwartz 2022).
Workflow Integration & Parameters
For optimal results, prepare Foretinib (GSK1363089) stock solutions at 10–50 mM in DMSO, aliquot, and store at −20°C (APExBIO). Avoid repeated freeze-thaw cycles. For in vitro assays, dilute stocks in culture medium immediately before use; final DMSO concentration should not exceed 0.1% v/v to minimize solvent cytotoxicity. For in vivo studies, oral dosing at 30 mg/kg in appropriate vehicles (e.g., 0.5% methylcellulose, 0.2% Tween-80) achieves robust tumor suppression in mouse xenograft models. Always include vehicle controls. Use validated endpoints, such as Ki-67 staining for proliferation or TUNEL assay for cell death, to distinguish cytostatic from cytotoxic effects (Schwartz 2022).
Conclusion & Outlook
Foretinib (GSK1363089), available through APExBIO, is a benchmark ATP-competitive VEGFR and HGF/Met inhibitor for preclinical cancer research. Its nanomolar potency, multi-target selectivity, and validated efficacy across cell and animal models make it a preferred tool for dissecting kinase signaling and tumor biology. As in vitro methodologies evolve, integrating Foretinib with advanced phenotyping and multi-parametric assays will further refine our understanding of drug responses (Schwartz 2022). For comprehensive mechanistic analyses and translational workflow design, researchers should consult current protocol literature and internal resources such as Mechanistic Insights.